This event occurs in the following :
Following the executive order on 13 September to lower drug prices in the United States, the battleground over US healthcare is taking shape and could fundamentally impact the outlook of the global pharmaceutical industry—all while the coronavirus disease 2019 (COVID-19) pandemic continues to dominate the political agenda.
Vice President, Industry Services & Life Sciences, GlobalData
Margaret Labban, Ph.D.
Life Sciences Senior Analyst, GlobalData
Director, Life Sciences Research, GlobalData
Managing Director – Consulting, Life Sciences, Economics and Country Risk, GlobalData
Consulting Associate Director, Life Sciences, GlobalData